insights_auto
Outlook: 37.5% bullish·0.0% bearish
Go to analysischevron_right
KVUE:NYSE
Kenvue Ord Shs
$19.31
0.00%
(0.00) 1D
Oct 30, 3:00:05 PM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
News stories
From web sources and news partners
Seeking Alpha
·
1 day ago
Kimberly-Clark: 2027 Recovery And Kenvue Synergies Make It A Buy (NASDAQ:KMB)
Stocks Down Under
·
1 day ago
Kenvue (NYSE:KVUE) Share Price, Forecast & Analysis
Profile
Kenvue Inc. is an American consumer health company. Formerly the Consumer Healthcare division of Johnson & Johnson, Kenvue owns well-known brands such as Aveeno, Band-Aid, Benadryl, Zyrtec, Johnson's, Listerine, Lactaid, Mylanta, Neutrogena, Trosyd, Calpol, Tylenol, and Visine. Kenvue is incorporated in Delaware and was originally headquartered in the Skillman section of Montgomery Township, New Jersey, before relocating to Summit, New Jersey.
Johnson & Johnson announced in November 2021 that it would spin off its consumer health division as a separate company. The new company was named Kenvue in September 2022, and its initial public offering took place in May 2023, raising $3.8 billion in the largest U.S. IPO since 2021, with an initial valuation of about $41 billion. Johnson & Johnson initially retained more than 90% ownership before completing a full separation through a share exchange in July 2023. Kenvue was subsequently added to the S&P 500 Dividend Aristocrats index.
CEO Thibaut Mongon initially led Kenvue, which employed about 22,200 people in 2022. Following Mongon’s termination in 2025, Kirk Perry was named interim CEO. Wikipedia